CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Ultrasound-mediated blood-brain barrier modulation enhances T-cell access but requires immune activation for effective CNS immunity.
Ultrasound-mediated blood-brain barrier modulation enhances T-cell access but requires immune activation for effective CNS immunity.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
免疫治疗在脑肿瘤中疗效有限,免疫准入受限、抗原异质性和局部免疫抑制制约了持久应答。低强度脉冲超声联合微泡(LIPU+MB)可短暂调节血脑屏障(BBB),并被广泛认为通过促进药物和免疫细胞进入中枢神经系统(CNS)来增强免疫治疗。
然而,仅增加解剖学上的准入是否足以产生有效的CNS免疫仍不清楚。在此,我们利用星形胶质细胞限制性抗原表达的转基因小鼠模型,证明仅调节BBB不足以在CNS中产生功能性T细胞免疫。尽管LIPU+MB使T细胞能够快速进入,但其积聚需要预先的T细胞活化和整合素依赖性机制,表明进入仍受经典免疫过程调控。
此外,由于CNS内抗原呈递细胞(APC)活化不足,T细胞无法持久存在。全身免疫佐剂(poly-ICLC和IL-2;PI)诱导APC活化,促进组织驻留记忆样分化,并支持持久的T细胞应答。LIPU+MB通过增加T细胞募集进一步增强这些应答,导致比单独PI更大的积聚。在机制上,骨髓来源APC的抗原呈递比小胶质细胞对CNS中抗原特异性T细胞的积聚和持久存在更为关键。在对CAR-T 细胞治疗耐药的抗原异质性胶质瘤模型中,将PI与BBB调节联合增强了免疫治疗的疗效,并伴随生存期延长和内源性肿瘤特异性T细胞应答,与表位扩展一致。
总之,这些发现明确了LIPU+MB在促进有效T细胞治疗方面的关键局限性,并证实BBB调节必须与系统性免疫激活相结合,才能支持CNS中T细胞介导的抗肿瘤免疫。
Immunotherapy shows limited efficacy in brain tumours, where restricted immune access, antigenic heterogeneity and local immunosuppression constrain durable responses. Low-intensity pulsed ultrasound with microbubbles (LIPU+MB) transiently modulates the blood-brain barrier (BBB) and is widely assumed to enhance immunotherapy by facilitating drug and immune cell penetration into the central nervous system (CNS).
However, whether increased anatomical access alone is sufficient to generate effective CNS immunity remains unclear.
Here, using a transgenic mouse model with astrocyte-restricted antigen expression, we showed that BBB modulation alone is insufficient to generate functional T-cell immunity in the CNS. Although LIPU+MB enabled rapid T-cell entry, accumulation required prior T-cell activation and integrin-dependent mechanisms, indicating that entry remains governed by canonical immune processes.
Moreover, T-cells failed to persist owing to insufficient activation of antigen-presenting cells (APCs) within the CNS. Systemic immune adjuvants (poly-ICLC and IL-2; PI) induced APC activation, promoted tissue-resident-memory-like differentiation and supported durable T-cell responses. LIPU+MB further enhanced these responses by increasing T-cell recruitment, resulting in greater accumulation than with PI alone.
Mechanistically, antigen presentation by bone marrow-derived APCs was more critical than that by microglia for the accumulation and persistence of antigen-specifc T-cells in the CNS. In antigenically heterogeneous glioma models resistant to CAR T-cell therapy, combining PI with BBB modulation enhanced the efficacy of immunotherapy, which was mirrored by prolonged survival and endogenous tumour-specific T-cell responses, consistent with epitope spreading.
Together, these findings define key limitations of LIPU+MB in enabling effective T-cell therapy and establish that BBB modulation must be coupled to systemic immune activation to support T-cell-mediated antitumour immunity in the CNS.
MEMBER ACCOUNT
登录成功会直接打开下一页。